Abaloparatide Injection (QLG2128)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Abaloparatide Injection (QLG2128), covering 2025-03-27 to 2025-03-27. Get the full timeline:
Most recent: Clinical Trial Update: To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture [Phase 3]